Romark constructs a new state-of-the-art facility located in Manati, Puerto Rico. The new manufacturing facility is estimated with an amount of more than US$80 million.
The manufacturing facility will be designed with an area approximately covering 35,000 square feet. The facility will be dedicated for the production of Alinia (nitazoxanide) tablets, 500 mg and Alinia (nitazoxanide) for Oral Suspension, 100 mg/5mL in the US market.
It will support the development and distribution of NT-300 (nitazoxanide extended-release tablets) an investigational new drug candidate, which is under clinical trials for the prevention and treatment of COVID-19 and other viral respiratory illnesses.
The new facility designed with advanced equipment will manufacture tablets, powders and other oral solid dosage forms. Moreover, this expansion will increase the capacity to develop and deliver medicines.
Once the construction of this new state-of-the-art facility is completed an additional 100 new employees will be positioned.